Swiss Garnier Life Sciences

What Swiss Garnier Life Sciences does

Swiss Garnier Life Sciences is an Indian pharmaceutical and nutraceutical Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) founded in 2006 and headquartered in Chennai, with 1,500+ employees. The group operates through three wholly-owned subsidiaries (Swiss Garnier Life Sciences, Swiss Garnier Biotech Private Limited, and Swiss Garnier Genexiaa Sciences Pvt Ltd) and runs four cGMP/PIC/WHO-GMP/EU-GMP-accredited manufacturing plants in Himachal Pradesh and Sikkim with combined annual capacity exceeding 10 billion tablets and capsules. The technology stack centers on multi-dosage-form manufacturing — tablets (uncoated, coated, enteric-coated, chewable, orally dissolving, effervescent), capsules (hard/soft gelatin, enteric-coated), liquids, ointments, and sachets — using PLC-controlled production lines, Proditec 360-degree tablet inspection, and Flaktwood air handling, plus proprietary drug delivery systems such as tablet-in-tablet and mouth-dissolving granules. Plant 4 in Rorathang, Sikkim was designed to Abbott Global specifications, embedding multinational-grade quality systems into the asset base.

The company generates revenue on a project-based B2B contract manufacturing and development model, selling CMO/CDMO services to global pharmaceutical, nutraceutical, and Ayurvedic/AYUSH clients. Approximately 400 product registrations have been filed across 40+ countries (Asia, Africa, LATAM, Europe), supported by 120+ CTD/ACTD dossiers and an in-house regulatory affairs team; the International Division (est. 2014) has compounded at over 100% annually and is projected to contribute at least 40% of revenue. Strategic partnerships — Abbott India (2014), Novartis (2021), Servier (2022), Lonza (proprietary ingredients), UC-II (joint health), and PepsiCo Australia (nutraceuticals) — anchor the customer base across enterprise pharma, FMCG, and supplement segments. The company has stated but undisclosed revenue, no public listing, and remains founder-owned under Chairman M.S. Devanathan.

Name

Swiss Garnier Life Sciences

Legal name

Swiss Garnier Life Sciences

Website

https://swissgarnier.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Swiss Garnier Life Sciences is an India-based pharmaceutical and nutraceutical CMO/CDMO operating four cGMP-accredited plants with 10+ billion tablets/capsules annual capacity, serving global pharma, nutraceutical, and Ayurvedic clients across 40+ countries via contract manufacturing, formulation development, and international regulatory registration services.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical and Nutraceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Contract pharmaceutical manufacturing
• Nutraceutical contract manufacturing
• Regulatory dossier preparation
• Innovative drug delivery systems
• Ayurvedic formulation manufacturing

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Organization (CMO) Services: Custom formulation manufacturing for pharmaceutical and nutraceutical companies. Services include custom-made formulations, unique dosage formats, and innovative packaging solutions for B2B clients.
2. Contract Development and Manufacturing Organization (CDMO) Services: Full-service product development from formulation design through manufacturing and regulatory support, serving pharmaceutical, nutraceutical, and Ayurvedic industries.
3. International Product Registrations: CTD/ACTD dossier development and registration services for international markets across 40+ countries.
4. Loan Licensing Services: Extended licensing and production services that allow clients to utilize manufacturing facilities without managing their own manufacturing infrastructure.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Swiss Garnier Life Sciences is a B2B Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) that produces pharmaceutical and nutraceutical formulations across tablets, capsules, liquids, sachets, ointments, and effervescents at four cGMP, WHO GMP, EU GMP, and PIC/S-accredited manufacturing facilities in Himachal Pradesh and Sikkim, India. It offers end-to-end services spanning formulation R&D, ACTD/CTD dossier development, bioequivalence study support, and international product registration across 40+ countries, plus loan-licensing arrangements that let clients use its plants without owning manufacturing infrastructure.

Product overview

Swiss Garnier Life Sciences operates as a global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical and nutraceutical industries. The company runs four manufacturing plants across India (Himachal Pradesh and Sikkim) with a combined annual capacity exceeding 10 billion tablets/capsules. Its product and service portfolio spans: (1) CMO/CDMO contract manufacturing services at four cGMP/PIC/S-accredited facilities (Plants 1–4), producing pharmaceuticals and nutraceuticals across tablets, capsules, liquids, sachets, and ointments; (2) R&D services for formulation development, dossier preparation (CTD/ACTD), and bioequivalence studies; (3) a pharmaceutical formulations portfolio covering 11 therapeutic areas (Cardiology, Anti-infectives, Dermatology, Diabetology, Gastroenterology, Neuro/Psychiatry, Orthopedics, Pain Management, Pulmonology, Urology, Gynecology) in multiple drug delivery formats; and (4) a nutraceuticals portfolio featuring personalized nutrition and bioactive compound formulations. The company maintains separate domestic (India) and international (40+ countries across Asia, Africa, LATAM, and Europe) business divisions.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Manufacturing (CMO Services) Contract manufacturing organization (CMO) services producing pharmaceutical and nutraceutical formulations across tablets, capsules, liquids, sachets, and ointments at four cGMP-compliant facilities in India, intended for pharmaceutical and nutraceutical client companies seeking compliant large-scale contract manufacturing.
• CDMO Services Contract Development and Manufacturing Organization (CDMO) services covering formulation development, ACTD/CTD dossier preparation, bioequivalence study support, and international regulatory filing assistance for pharmaceutical, nutraceutical, and Ayurvedic client companies.
• R&D Services Research and development services for pharmaceutical and nutraceutical formulations, including product design, patented ingredient incorporation (e.g., via Lonza and UC-II partnerships), unique dosage form development, and ACTD/CTD dossier preparation with bioequivalence study support.
• Plant 1 — Pharmaceutical CMO Facility (Mehatpur, Himachal Pradesh) Pharmaceutical contract manufacturing facility located in Mehatpur, Himachal Pradesh (operating since 2006), producing uncoated tablets (780M), coated tablets (260M), capsules (450M), sachets (120M), liquids (40M), and ointments (30M) annually (1,680 million units total) for B2B pharmaceutical clients.
• Plant 2 — Nutraceutical and Ayush CMO Facility (Swiss Garnier Biotech Private Ltd) Specialized nutraceutical and Ayush product manufacturing facility producing uncoated tablets (1,300M), coated tablets (450M), capsules (460M), sachets (270M), and liquids (40M) annually (2,520 million units total), designed to FSSAI and Ayush standards for nutraceutical, herbal, and bioactive compound formulations.
• Plant 3 — cGMP Pharmaceutical Facility (Swiss Garnier Genexiaa Sciences Pvt Ltd, Unit I, Mamring, Sikkim) cGMP pharmaceutical formulation facility in Mamring, Sikkim (operational since 2013) with 100,000 sq ft built-up area on 2.7 acres, producing tablets (280M), capsules (90M), and dry powder sachets (15M) annually, primarily serving domestic B2B markets.
• Plant 4 — Advanced CMO/CDMO Facility (Swiss Garnier Genexiaa Sciences Pvt Ltd, Unit II, Rorathang, Sikkim) Advanced CMO/CDMO facility in Rorathang, Sikkim (operational since 2017) with 273,000 sq ft built-up area on 7.30 acres and total annual capacity of 6 billion tablets/capsules across two shifts, producing uncoated tablets (3,530M), coated tablets (3,200M), capsules (450M), sachets (90M), and effervescent tablets (300M).
• Domestic CMO/CDMO Services (India) Contract manufacturing and development services for Indian pharmaceutical and nutraceutical clients, offering custom formulations, unique dosage formats (tablets, capsules, powders, oral liquids), innovative packaging (blisters, bottles, sachets), and regulatory compliance with DCGI (pharmaceuticals) and FSSAI (nutraceuticals).
• International Business Division International CMO/CDMO division present in 40+ countries across Asia, Africa, LATAM, and Europe with PIC/S accreditation and multiple international approvals, managing 120+ CTD/ACTD dossiers and approximately 400 registrations globally, with 100%+ annual growth and projected to contribute at least 40% of company revenue.
• Pharmaceutical Formulations Portfolio Pharmaceutical formulation portfolio spanning 11 therapeutic areas (Cardiology 116 molecules, Anti-infectives 34, Dermatology 37, Diabetology 73, Gastroenterology 85, Neuro/Psychiatry 96, Orthopedics, Pain Management 45, Pulmonology 41, Urology, Gynecology) across multiple dosage formats including standard/coated/enteric-coated tablets, hard/soft gelatin capsules, oral liquids and drops, ointments, sachets, and effervescent tablets, with innovative drug delivery systems such as enteric-coated capsules, tablet-in-tablet, chewable tablets, sublingual dissolving tablets, and orally dissolving granules for B2B clients.
• Nutraceutical Formulations Portfolio Nutraceutical product portfolio of innovative formulations combining scientifically validated bioactive compounds for targeted health benefits (immunity, digestion, cardiovascular support, joint health), with personalized nutrition solutions and dosage formats including chewable tablets, effervescent tablets, oral dissolving tablets, sublingual tablets, sachets, capsules, and syrups for nutraceutical and functional food client companies.

Quantifiable outcome

• 100%+ annual growth in International division
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Three partnerships are on record, tiered core.

• Abbott India LimitedcoreStrategic or Co-development Partner · 1 January 2014Technical collaboration established in 2014 for manufacturing guidance and regulatory support. Plant 4 was designed based on Abbott Global guidelines with technical team support, incorporating safety standards including glass wool instead of polyurethane foam and equipment designed according to Abbott Global technical specifications.
• LonzacoreTechnology or IntegrationStrategic collaboration with Lonza for integration of patented and clinically validated ingredients into Swiss Garnier's formulations. This partnership enables access to proprietary active pharmaceutical and nutraceutical ingredients, supporting innovative product development across pharmaceutical and nutraceutical segments.
• UC-IIcoreTechnology or IntegrationPartnership for joint health formulations using UC-II collagen ingredients, launching innovative formulations designed to address specific health challenges in joint health segment.

Scale indicators10 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Piramal Pharma Solutions: Piramal's CDMO arm offers contract development and manufacturing for oral solids, injectables, and APIs across global pharma customers. Directly comparable as an Indian-headquartered CMO/CDMO with multi-continent regulatory approvals and enterprise pharma clients.
• Divis Laboratories: One of India's largest API and formulation CDMOs serving global generics and innovator pharma. Comparable as an India-based, GMP-certified, export-heavy contract manufacturer competing for similar multinational formulation customers.
• Syngene International: Bengaluru-based CRO/CDMO providing formulation development, manufacturing, and regulatory services to global pharma. Closely comparable end-to-end CDMO model with international regulatory dossiers.
• Jubilant Pharmova: Indian pharma CDMO offering sterile injectables, APIs, and oral solid manufacturing with USFDA/EMA approvals. Overlaps with Swiss Garnier's contract manufacturing services for global pharma clients.
• Neuland Laboratories: Hyderabad-based CDMO focused on APIs and custom synthesis for global pharma. Comparable as an India-headquartered GMP-certified contract manufacturer serving multinational pharma customers.
• Suven Pharmaceuticals: Hyderabad-based CRAMS/CDMO offering API and formulation services to global innovators. Comparable as a focused Indian CDMO serving multinational pharma customers with regulatory-led international expansion.
• Granules India: Indian formulations CDMO specializing in high-volume oral solids (tablets, capsules) for global generics customers. Closely comparable business model of large-scale tablet/capsule contract manufacturing for international pharma.

Broad incumbents

• Aurobindo Pharma: Vertically integrated Indian generics major with significant contract and export manufacturing footprint. Overlaps with Swiss Garnier on oral solid generics contract manufacturing but operates on a much larger, branded-plus-generics scale.
• Lonza Group: Global CDMO leader and Swiss Garnier's named technology partner for patented ingredients. Compares as a large incumbent CMO/CDMO whose ingredients feed into Swiss Garnier's formulations, setting the global benchmark for capability and scale.

Emerging players

• Cohance Lifesciences: Recently rebranded CDMO/API platform formed from API Holdings. Competes for similar Indian CDMO customers with APIs and formulations across therapeutic areas overlapping Swiss Garnier's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance28 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiss Garnier Life Sciences